Research ArticleArticle
Open Access
Safety and Efficacy of Tofacitinib, an Oral Janus Kinase Inhibitor, for the Treatment of Rheumatoid Arthritis in Open-label, Longterm Extension Studies
Jürgen Wollenhaupt, Joel Silverfield, Eun Bong Lee, Jeffrey R. Curtis, Susan P. Wood, Koshika Soma, Chudy I. Nduaka, Birgitta Benda, David Gruben, Hiroyuki Nakamura, Yoshihiro Komuro, Samuel H. Zwillich, Lisy Wang and Richard J. Riese
The Journal of Rheumatology April 2014, jrheum.130683; DOI: https://doi.org/10.3899/jrheum.130683
Jürgen Wollenhaupt
From the Schoen Klinik Hamburg, Hamburg, Germany; Healthpoint Medical Group, Tampa, Florida, USA; Seoul National University, Seoul, Republic of Korea; The University of Alabama at Birmingham, Birmingham, Alabama; Pfizer Inc., Groton, Connecticut; Pfizer Inc., Collegeville, Pennsylvania, USA; Pfizer Japan Inc., Tokyo, Japan. Funded by Pfizer Inc. J. Wollenhaupt has served as a consultant and member of the Speaker’s bureau for Abbott, Chugai, Pfizer Inc., Roche, and UCB. J. Silverfield has received research support from Pfizer Inc. E.B. Lee has served as a consultant for Pfizer Inc. J.R. Curtis has served as a consultant for, and has received research support from Pfizer Inc.; S.P. Wood, K. Soma, C.I. Nduaka, B. Benda, D. Gruben, H. Nakamura, Y. Komuro, S.H. Zwillich, L. Wang, and R.J. Riese are employees of Pfizer Inc. and hold stock/stock options in Pfizer Inc. Editorial support was provided by Karen Irving at Complete Medical Communications and was funded by Pfizer Inc. J. Wollenhaupt, MD, Head of Department of Rheumatology and Clinical Immunology, Schoen Klinik Hamburg; J. Silverfield, MD, Partner, Healthpoint Medical Group; E.B. Lee, MD, PhD, Professor of Medicine, Seoul National University; J.R. Curtis, MD, MS, MPH, Associate Professor of Medicine, The University of Alabama at Birmingham; S.P. Wood, RN, MA, Clinician; K. Soma, MD, MFPM, Director, Clinical Development; C.I. Nduaka, DVM, PhD, Medical Director; D. Gruben, PhD, Statistician; S.H. Zwillich, MD, Senior Director, Medicines Development Group Lead for Tofacitinib RA; L. Wang, MD, Clinician/Director; R.J. Riese, MD, PhD, Senior Director, Clinical Development, Pfizer Inc., Groton; B. Benda, MD, PhD, Senior Medical Director, Pfizer Inc., Collegeville; H. Nakamura, BS, Japan Clinical Lead; Y. Komuro, BS, Japan Clinical Lead, Pfizer Japan Inc. Address correspondence to Prof. Wollenhaupt, Head of Department of Rheumatology and Clinical Immunology, Schoen Klinik Hamburg, Teaching Hospital of the University of Hamburg, Dehnhaide 120, 11081 Hamburg, Germany. E-mail: Wollenhaupt@rheumatologikum.de. Full Release Article. For details see Reprints/Permissions at jrheum.org Accepted for publication November 19, 2013.
Joel Silverfield
From the Schoen Klinik Hamburg, Hamburg, Germany; Healthpoint Medical Group, Tampa, Florida, USA; Seoul National University, Seoul, Republic of Korea; The University of Alabama at Birmingham, Birmingham, Alabama; Pfizer Inc., Groton, Connecticut; Pfizer Inc., Collegeville, Pennsylvania, USA; Pfizer Japan Inc., Tokyo, Japan. Funded by Pfizer Inc. J. Wollenhaupt has served as a consultant and member of the Speaker’s bureau for Abbott, Chugai, Pfizer Inc., Roche, and UCB. J. Silverfield has received research support from Pfizer Inc. E.B. Lee has served as a consultant for Pfizer Inc. J.R. Curtis has served as a consultant for, and has received research support from Pfizer Inc.; S.P. Wood, K. Soma, C.I. Nduaka, B. Benda, D. Gruben, H. Nakamura, Y. Komuro, S.H. Zwillich, L. Wang, and R.J. Riese are employees of Pfizer Inc. and hold stock/stock options in Pfizer Inc. Editorial support was provided by Karen Irving at Complete Medical Communications and was funded by Pfizer Inc. J. Wollenhaupt, MD, Head of Department of Rheumatology and Clinical Immunology, Schoen Klinik Hamburg; J. Silverfield, MD, Partner, Healthpoint Medical Group; E.B. Lee, MD, PhD, Professor of Medicine, Seoul National University; J.R. Curtis, MD, MS, MPH, Associate Professor of Medicine, The University of Alabama at Birmingham; S.P. Wood, RN, MA, Clinician; K. Soma, MD, MFPM, Director, Clinical Development; C.I. Nduaka, DVM, PhD, Medical Director; D. Gruben, PhD, Statistician; S.H. Zwillich, MD, Senior Director, Medicines Development Group Lead for Tofacitinib RA; L. Wang, MD, Clinician/Director; R.J. Riese, MD, PhD, Senior Director, Clinical Development, Pfizer Inc., Groton; B. Benda, MD, PhD, Senior Medical Director, Pfizer Inc., Collegeville; H. Nakamura, BS, Japan Clinical Lead; Y. Komuro, BS, Japan Clinical Lead, Pfizer Japan Inc. Address correspondence to Prof. Wollenhaupt, Head of Department of Rheumatology and Clinical Immunology, Schoen Klinik Hamburg, Teaching Hospital of the University of Hamburg, Dehnhaide 120, 11081 Hamburg, Germany. E-mail: Wollenhaupt@rheumatologikum.de. Full Release Article. For details see Reprints/Permissions at jrheum.org Accepted for publication November 19, 2013.
Eun Bong Lee
From the Schoen Klinik Hamburg, Hamburg, Germany; Healthpoint Medical Group, Tampa, Florida, USA; Seoul National University, Seoul, Republic of Korea; The University of Alabama at Birmingham, Birmingham, Alabama; Pfizer Inc., Groton, Connecticut; Pfizer Inc., Collegeville, Pennsylvania, USA; Pfizer Japan Inc., Tokyo, Japan. Funded by Pfizer Inc. J. Wollenhaupt has served as a consultant and member of the Speaker’s bureau for Abbott, Chugai, Pfizer Inc., Roche, and UCB. J. Silverfield has received research support from Pfizer Inc. E.B. Lee has served as a consultant for Pfizer Inc. J.R. Curtis has served as a consultant for, and has received research support from Pfizer Inc.; S.P. Wood, K. Soma, C.I. Nduaka, B. Benda, D. Gruben, H. Nakamura, Y. Komuro, S.H. Zwillich, L. Wang, and R.J. Riese are employees of Pfizer Inc. and hold stock/stock options in Pfizer Inc. Editorial support was provided by Karen Irving at Complete Medical Communications and was funded by Pfizer Inc. J. Wollenhaupt, MD, Head of Department of Rheumatology and Clinical Immunology, Schoen Klinik Hamburg; J. Silverfield, MD, Partner, Healthpoint Medical Group; E.B. Lee, MD, PhD, Professor of Medicine, Seoul National University; J.R. Curtis, MD, MS, MPH, Associate Professor of Medicine, The University of Alabama at Birmingham; S.P. Wood, RN, MA, Clinician; K. Soma, MD, MFPM, Director, Clinical Development; C.I. Nduaka, DVM, PhD, Medical Director; D. Gruben, PhD, Statistician; S.H. Zwillich, MD, Senior Director, Medicines Development Group Lead for Tofacitinib RA; L. Wang, MD, Clinician/Director; R.J. Riese, MD, PhD, Senior Director, Clinical Development, Pfizer Inc., Groton; B. Benda, MD, PhD, Senior Medical Director, Pfizer Inc., Collegeville; H. Nakamura, BS, Japan Clinical Lead; Y. Komuro, BS, Japan Clinical Lead, Pfizer Japan Inc. Address correspondence to Prof. Wollenhaupt, Head of Department of Rheumatology and Clinical Immunology, Schoen Klinik Hamburg, Teaching Hospital of the University of Hamburg, Dehnhaide 120, 11081 Hamburg, Germany. E-mail: Wollenhaupt@rheumatologikum.de. Full Release Article. For details see Reprints/Permissions at jrheum.org Accepted for publication November 19, 2013.
Jeffrey R. Curtis
From the Schoen Klinik Hamburg, Hamburg, Germany; Healthpoint Medical Group, Tampa, Florida, USA; Seoul National University, Seoul, Republic of Korea; The University of Alabama at Birmingham, Birmingham, Alabama; Pfizer Inc., Groton, Connecticut; Pfizer Inc., Collegeville, Pennsylvania, USA; Pfizer Japan Inc., Tokyo, Japan. Funded by Pfizer Inc. J. Wollenhaupt has served as a consultant and member of the Speaker’s bureau for Abbott, Chugai, Pfizer Inc., Roche, and UCB. J. Silverfield has received research support from Pfizer Inc. E.B. Lee has served as a consultant for Pfizer Inc. J.R. Curtis has served as a consultant for, and has received research support from Pfizer Inc.; S.P. Wood, K. Soma, C.I. Nduaka, B. Benda, D. Gruben, H. Nakamura, Y. Komuro, S.H. Zwillich, L. Wang, and R.J. Riese are employees of Pfizer Inc. and hold stock/stock options in Pfizer Inc. Editorial support was provided by Karen Irving at Complete Medical Communications and was funded by Pfizer Inc. J. Wollenhaupt, MD, Head of Department of Rheumatology and Clinical Immunology, Schoen Klinik Hamburg; J. Silverfield, MD, Partner, Healthpoint Medical Group; E.B. Lee, MD, PhD, Professor of Medicine, Seoul National University; J.R. Curtis, MD, MS, MPH, Associate Professor of Medicine, The University of Alabama at Birmingham; S.P. Wood, RN, MA, Clinician; K. Soma, MD, MFPM, Director, Clinical Development; C.I. Nduaka, DVM, PhD, Medical Director; D. Gruben, PhD, Statistician; S.H. Zwillich, MD, Senior Director, Medicines Development Group Lead for Tofacitinib RA; L. Wang, MD, Clinician/Director; R.J. Riese, MD, PhD, Senior Director, Clinical Development, Pfizer Inc., Groton; B. Benda, MD, PhD, Senior Medical Director, Pfizer Inc., Collegeville; H. Nakamura, BS, Japan Clinical Lead; Y. Komuro, BS, Japan Clinical Lead, Pfizer Japan Inc. Address correspondence to Prof. Wollenhaupt, Head of Department of Rheumatology and Clinical Immunology, Schoen Klinik Hamburg, Teaching Hospital of the University of Hamburg, Dehnhaide 120, 11081 Hamburg, Germany. E-mail: Wollenhaupt@rheumatologikum.de. Full Release Article. For details see Reprints/Permissions at jrheum.org Accepted for publication November 19, 2013.
Susan P. Wood
From the Schoen Klinik Hamburg, Hamburg, Germany; Healthpoint Medical Group, Tampa, Florida, USA; Seoul National University, Seoul, Republic of Korea; The University of Alabama at Birmingham, Birmingham, Alabama; Pfizer Inc., Groton, Connecticut; Pfizer Inc., Collegeville, Pennsylvania, USA; Pfizer Japan Inc., Tokyo, Japan. Funded by Pfizer Inc. J. Wollenhaupt has served as a consultant and member of the Speaker’s bureau for Abbott, Chugai, Pfizer Inc., Roche, and UCB. J. Silverfield has received research support from Pfizer Inc. E.B. Lee has served as a consultant for Pfizer Inc. J.R. Curtis has served as a consultant for, and has received research support from Pfizer Inc.; S.P. Wood, K. Soma, C.I. Nduaka, B. Benda, D. Gruben, H. Nakamura, Y. Komuro, S.H. Zwillich, L. Wang, and R.J. Riese are employees of Pfizer Inc. and hold stock/stock options in Pfizer Inc. Editorial support was provided by Karen Irving at Complete Medical Communications and was funded by Pfizer Inc. J. Wollenhaupt, MD, Head of Department of Rheumatology and Clinical Immunology, Schoen Klinik Hamburg; J. Silverfield, MD, Partner, Healthpoint Medical Group; E.B. Lee, MD, PhD, Professor of Medicine, Seoul National University; J.R. Curtis, MD, MS, MPH, Associate Professor of Medicine, The University of Alabama at Birmingham; S.P. Wood, RN, MA, Clinician; K. Soma, MD, MFPM, Director, Clinical Development; C.I. Nduaka, DVM, PhD, Medical Director; D. Gruben, PhD, Statistician; S.H. Zwillich, MD, Senior Director, Medicines Development Group Lead for Tofacitinib RA; L. Wang, MD, Clinician/Director; R.J. Riese, MD, PhD, Senior Director, Clinical Development, Pfizer Inc., Groton; B. Benda, MD, PhD, Senior Medical Director, Pfizer Inc., Collegeville; H. Nakamura, BS, Japan Clinical Lead; Y. Komuro, BS, Japan Clinical Lead, Pfizer Japan Inc. Address correspondence to Prof. Wollenhaupt, Head of Department of Rheumatology and Clinical Immunology, Schoen Klinik Hamburg, Teaching Hospital of the University of Hamburg, Dehnhaide 120, 11081 Hamburg, Germany. E-mail: Wollenhaupt@rheumatologikum.de. Full Release Article. For details see Reprints/Permissions at jrheum.org Accepted for publication November 19, 2013.
Koshika Soma
From the Schoen Klinik Hamburg, Hamburg, Germany; Healthpoint Medical Group, Tampa, Florida, USA; Seoul National University, Seoul, Republic of Korea; The University of Alabama at Birmingham, Birmingham, Alabama; Pfizer Inc., Groton, Connecticut; Pfizer Inc., Collegeville, Pennsylvania, USA; Pfizer Japan Inc., Tokyo, Japan. Funded by Pfizer Inc. J. Wollenhaupt has served as a consultant and member of the Speaker’s bureau for Abbott, Chugai, Pfizer Inc., Roche, and UCB. J. Silverfield has received research support from Pfizer Inc. E.B. Lee has served as a consultant for Pfizer Inc. J.R. Curtis has served as a consultant for, and has received research support from Pfizer Inc.; S.P. Wood, K. Soma, C.I. Nduaka, B. Benda, D. Gruben, H. Nakamura, Y. Komuro, S.H. Zwillich, L. Wang, and R.J. Riese are employees of Pfizer Inc. and hold stock/stock options in Pfizer Inc. Editorial support was provided by Karen Irving at Complete Medical Communications and was funded by Pfizer Inc. J. Wollenhaupt, MD, Head of Department of Rheumatology and Clinical Immunology, Schoen Klinik Hamburg; J. Silverfield, MD, Partner, Healthpoint Medical Group; E.B. Lee, MD, PhD, Professor of Medicine, Seoul National University; J.R. Curtis, MD, MS, MPH, Associate Professor of Medicine, The University of Alabama at Birmingham; S.P. Wood, RN, MA, Clinician; K. Soma, MD, MFPM, Director, Clinical Development; C.I. Nduaka, DVM, PhD, Medical Director; D. Gruben, PhD, Statistician; S.H. Zwillich, MD, Senior Director, Medicines Development Group Lead for Tofacitinib RA; L. Wang, MD, Clinician/Director; R.J. Riese, MD, PhD, Senior Director, Clinical Development, Pfizer Inc., Groton; B. Benda, MD, PhD, Senior Medical Director, Pfizer Inc., Collegeville; H. Nakamura, BS, Japan Clinical Lead; Y. Komuro, BS, Japan Clinical Lead, Pfizer Japan Inc. Address correspondence to Prof. Wollenhaupt, Head of Department of Rheumatology and Clinical Immunology, Schoen Klinik Hamburg, Teaching Hospital of the University of Hamburg, Dehnhaide 120, 11081 Hamburg, Germany. E-mail: Wollenhaupt@rheumatologikum.de. Full Release Article. For details see Reprints/Permissions at jrheum.org Accepted for publication November 19, 2013.
Chudy I. Nduaka
From the Schoen Klinik Hamburg, Hamburg, Germany; Healthpoint Medical Group, Tampa, Florida, USA; Seoul National University, Seoul, Republic of Korea; The University of Alabama at Birmingham, Birmingham, Alabama; Pfizer Inc., Groton, Connecticut; Pfizer Inc., Collegeville, Pennsylvania, USA; Pfizer Japan Inc., Tokyo, Japan. Funded by Pfizer Inc. J. Wollenhaupt has served as a consultant and member of the Speaker’s bureau for Abbott, Chugai, Pfizer Inc., Roche, and UCB. J. Silverfield has received research support from Pfizer Inc. E.B. Lee has served as a consultant for Pfizer Inc. J.R. Curtis has served as a consultant for, and has received research support from Pfizer Inc.; S.P. Wood, K. Soma, C.I. Nduaka, B. Benda, D. Gruben, H. Nakamura, Y. Komuro, S.H. Zwillich, L. Wang, and R.J. Riese are employees of Pfizer Inc. and hold stock/stock options in Pfizer Inc. Editorial support was provided by Karen Irving at Complete Medical Communications and was funded by Pfizer Inc. J. Wollenhaupt, MD, Head of Department of Rheumatology and Clinical Immunology, Schoen Klinik Hamburg; J. Silverfield, MD, Partner, Healthpoint Medical Group; E.B. Lee, MD, PhD, Professor of Medicine, Seoul National University; J.R. Curtis, MD, MS, MPH, Associate Professor of Medicine, The University of Alabama at Birmingham; S.P. Wood, RN, MA, Clinician; K. Soma, MD, MFPM, Director, Clinical Development; C.I. Nduaka, DVM, PhD, Medical Director; D. Gruben, PhD, Statistician; S.H. Zwillich, MD, Senior Director, Medicines Development Group Lead for Tofacitinib RA; L. Wang, MD, Clinician/Director; R.J. Riese, MD, PhD, Senior Director, Clinical Development, Pfizer Inc., Groton; B. Benda, MD, PhD, Senior Medical Director, Pfizer Inc., Collegeville; H. Nakamura, BS, Japan Clinical Lead; Y. Komuro, BS, Japan Clinical Lead, Pfizer Japan Inc. Address correspondence to Prof. Wollenhaupt, Head of Department of Rheumatology and Clinical Immunology, Schoen Klinik Hamburg, Teaching Hospital of the University of Hamburg, Dehnhaide 120, 11081 Hamburg, Germany. E-mail: Wollenhaupt@rheumatologikum.de. Full Release Article. For details see Reprints/Permissions at jrheum.org Accepted for publication November 19, 2013.
Birgitta Benda
From the Schoen Klinik Hamburg, Hamburg, Germany; Healthpoint Medical Group, Tampa, Florida, USA; Seoul National University, Seoul, Republic of Korea; The University of Alabama at Birmingham, Birmingham, Alabama; Pfizer Inc., Groton, Connecticut; Pfizer Inc., Collegeville, Pennsylvania, USA; Pfizer Japan Inc., Tokyo, Japan. Funded by Pfizer Inc. J. Wollenhaupt has served as a consultant and member of the Speaker’s bureau for Abbott, Chugai, Pfizer Inc., Roche, and UCB. J. Silverfield has received research support from Pfizer Inc. E.B. Lee has served as a consultant for Pfizer Inc. J.R. Curtis has served as a consultant for, and has received research support from Pfizer Inc.; S.P. Wood, K. Soma, C.I. Nduaka, B. Benda, D. Gruben, H. Nakamura, Y. Komuro, S.H. Zwillich, L. Wang, and R.J. Riese are employees of Pfizer Inc. and hold stock/stock options in Pfizer Inc. Editorial support was provided by Karen Irving at Complete Medical Communications and was funded by Pfizer Inc. J. Wollenhaupt, MD, Head of Department of Rheumatology and Clinical Immunology, Schoen Klinik Hamburg; J. Silverfield, MD, Partner, Healthpoint Medical Group; E.B. Lee, MD, PhD, Professor of Medicine, Seoul National University; J.R. Curtis, MD, MS, MPH, Associate Professor of Medicine, The University of Alabama at Birmingham; S.P. Wood, RN, MA, Clinician; K. Soma, MD, MFPM, Director, Clinical Development; C.I. Nduaka, DVM, PhD, Medical Director; D. Gruben, PhD, Statistician; S.H. Zwillich, MD, Senior Director, Medicines Development Group Lead for Tofacitinib RA; L. Wang, MD, Clinician/Director; R.J. Riese, MD, PhD, Senior Director, Clinical Development, Pfizer Inc., Groton; B. Benda, MD, PhD, Senior Medical Director, Pfizer Inc., Collegeville; H. Nakamura, BS, Japan Clinical Lead; Y. Komuro, BS, Japan Clinical Lead, Pfizer Japan Inc. Address correspondence to Prof. Wollenhaupt, Head of Department of Rheumatology and Clinical Immunology, Schoen Klinik Hamburg, Teaching Hospital of the University of Hamburg, Dehnhaide 120, 11081 Hamburg, Germany. E-mail: Wollenhaupt@rheumatologikum.de. Full Release Article. For details see Reprints/Permissions at jrheum.org Accepted for publication November 19, 2013.
David Gruben
From the Schoen Klinik Hamburg, Hamburg, Germany; Healthpoint Medical Group, Tampa, Florida, USA; Seoul National University, Seoul, Republic of Korea; The University of Alabama at Birmingham, Birmingham, Alabama; Pfizer Inc., Groton, Connecticut; Pfizer Inc., Collegeville, Pennsylvania, USA; Pfizer Japan Inc., Tokyo, Japan. Funded by Pfizer Inc. J. Wollenhaupt has served as a consultant and member of the Speaker’s bureau for Abbott, Chugai, Pfizer Inc., Roche, and UCB. J. Silverfield has received research support from Pfizer Inc. E.B. Lee has served as a consultant for Pfizer Inc. J.R. Curtis has served as a consultant for, and has received research support from Pfizer Inc.; S.P. Wood, K. Soma, C.I. Nduaka, B. Benda, D. Gruben, H. Nakamura, Y. Komuro, S.H. Zwillich, L. Wang, and R.J. Riese are employees of Pfizer Inc. and hold stock/stock options in Pfizer Inc. Editorial support was provided by Karen Irving at Complete Medical Communications and was funded by Pfizer Inc. J. Wollenhaupt, MD, Head of Department of Rheumatology and Clinical Immunology, Schoen Klinik Hamburg; J. Silverfield, MD, Partner, Healthpoint Medical Group; E.B. Lee, MD, PhD, Professor of Medicine, Seoul National University; J.R. Curtis, MD, MS, MPH, Associate Professor of Medicine, The University of Alabama at Birmingham; S.P. Wood, RN, MA, Clinician; K. Soma, MD, MFPM, Director, Clinical Development; C.I. Nduaka, DVM, PhD, Medical Director; D. Gruben, PhD, Statistician; S.H. Zwillich, MD, Senior Director, Medicines Development Group Lead for Tofacitinib RA; L. Wang, MD, Clinician/Director; R.J. Riese, MD, PhD, Senior Director, Clinical Development, Pfizer Inc., Groton; B. Benda, MD, PhD, Senior Medical Director, Pfizer Inc., Collegeville; H. Nakamura, BS, Japan Clinical Lead; Y. Komuro, BS, Japan Clinical Lead, Pfizer Japan Inc. Address correspondence to Prof. Wollenhaupt, Head of Department of Rheumatology and Clinical Immunology, Schoen Klinik Hamburg, Teaching Hospital of the University of Hamburg, Dehnhaide 120, 11081 Hamburg, Germany. E-mail: Wollenhaupt@rheumatologikum.de. Full Release Article. For details see Reprints/Permissions at jrheum.org Accepted for publication November 19, 2013.
Hiroyuki Nakamura
From the Schoen Klinik Hamburg, Hamburg, Germany; Healthpoint Medical Group, Tampa, Florida, USA; Seoul National University, Seoul, Republic of Korea; The University of Alabama at Birmingham, Birmingham, Alabama; Pfizer Inc., Groton, Connecticut; Pfizer Inc., Collegeville, Pennsylvania, USA; Pfizer Japan Inc., Tokyo, Japan. Funded by Pfizer Inc. J. Wollenhaupt has served as a consultant and member of the Speaker’s bureau for Abbott, Chugai, Pfizer Inc., Roche, and UCB. J. Silverfield has received research support from Pfizer Inc. E.B. Lee has served as a consultant for Pfizer Inc. J.R. Curtis has served as a consultant for, and has received research support from Pfizer Inc.; S.P. Wood, K. Soma, C.I. Nduaka, B. Benda, D. Gruben, H. Nakamura, Y. Komuro, S.H. Zwillich, L. Wang, and R.J. Riese are employees of Pfizer Inc. and hold stock/stock options in Pfizer Inc. Editorial support was provided by Karen Irving at Complete Medical Communications and was funded by Pfizer Inc. J. Wollenhaupt, MD, Head of Department of Rheumatology and Clinical Immunology, Schoen Klinik Hamburg; J. Silverfield, MD, Partner, Healthpoint Medical Group; E.B. Lee, MD, PhD, Professor of Medicine, Seoul National University; J.R. Curtis, MD, MS, MPH, Associate Professor of Medicine, The University of Alabama at Birmingham; S.P. Wood, RN, MA, Clinician; K. Soma, MD, MFPM, Director, Clinical Development; C.I. Nduaka, DVM, PhD, Medical Director; D. Gruben, PhD, Statistician; S.H. Zwillich, MD, Senior Director, Medicines Development Group Lead for Tofacitinib RA; L. Wang, MD, Clinician/Director; R.J. Riese, MD, PhD, Senior Director, Clinical Development, Pfizer Inc., Groton; B. Benda, MD, PhD, Senior Medical Director, Pfizer Inc., Collegeville; H. Nakamura, BS, Japan Clinical Lead; Y. Komuro, BS, Japan Clinical Lead, Pfizer Japan Inc. Address correspondence to Prof. Wollenhaupt, Head of Department of Rheumatology and Clinical Immunology, Schoen Klinik Hamburg, Teaching Hospital of the University of Hamburg, Dehnhaide 120, 11081 Hamburg, Germany. E-mail: Wollenhaupt@rheumatologikum.de. Full Release Article. For details see Reprints/Permissions at jrheum.org Accepted for publication November 19, 2013.
Yoshihiro Komuro
From the Schoen Klinik Hamburg, Hamburg, Germany; Healthpoint Medical Group, Tampa, Florida, USA; Seoul National University, Seoul, Republic of Korea; The University of Alabama at Birmingham, Birmingham, Alabama; Pfizer Inc., Groton, Connecticut; Pfizer Inc., Collegeville, Pennsylvania, USA; Pfizer Japan Inc., Tokyo, Japan. Funded by Pfizer Inc. J. Wollenhaupt has served as a consultant and member of the Speaker’s bureau for Abbott, Chugai, Pfizer Inc., Roche, and UCB. J. Silverfield has received research support from Pfizer Inc. E.B. Lee has served as a consultant for Pfizer Inc. J.R. Curtis has served as a consultant for, and has received research support from Pfizer Inc.; S.P. Wood, K. Soma, C.I. Nduaka, B. Benda, D. Gruben, H. Nakamura, Y. Komuro, S.H. Zwillich, L. Wang, and R.J. Riese are employees of Pfizer Inc. and hold stock/stock options in Pfizer Inc. Editorial support was provided by Karen Irving at Complete Medical Communications and was funded by Pfizer Inc. J. Wollenhaupt, MD, Head of Department of Rheumatology and Clinical Immunology, Schoen Klinik Hamburg; J. Silverfield, MD, Partner, Healthpoint Medical Group; E.B. Lee, MD, PhD, Professor of Medicine, Seoul National University; J.R. Curtis, MD, MS, MPH, Associate Professor of Medicine, The University of Alabama at Birmingham; S.P. Wood, RN, MA, Clinician; K. Soma, MD, MFPM, Director, Clinical Development; C.I. Nduaka, DVM, PhD, Medical Director; D. Gruben, PhD, Statistician; S.H. Zwillich, MD, Senior Director, Medicines Development Group Lead for Tofacitinib RA; L. Wang, MD, Clinician/Director; R.J. Riese, MD, PhD, Senior Director, Clinical Development, Pfizer Inc., Groton; B. Benda, MD, PhD, Senior Medical Director, Pfizer Inc., Collegeville; H. Nakamura, BS, Japan Clinical Lead; Y. Komuro, BS, Japan Clinical Lead, Pfizer Japan Inc. Address correspondence to Prof. Wollenhaupt, Head of Department of Rheumatology and Clinical Immunology, Schoen Klinik Hamburg, Teaching Hospital of the University of Hamburg, Dehnhaide 120, 11081 Hamburg, Germany. E-mail: Wollenhaupt@rheumatologikum.de. Full Release Article. For details see Reprints/Permissions at jrheum.org Accepted for publication November 19, 2013.
Samuel H. Zwillich
From the Schoen Klinik Hamburg, Hamburg, Germany; Healthpoint Medical Group, Tampa, Florida, USA; Seoul National University, Seoul, Republic of Korea; The University of Alabama at Birmingham, Birmingham, Alabama; Pfizer Inc., Groton, Connecticut; Pfizer Inc., Collegeville, Pennsylvania, USA; Pfizer Japan Inc., Tokyo, Japan. Funded by Pfizer Inc. J. Wollenhaupt has served as a consultant and member of the Speaker’s bureau for Abbott, Chugai, Pfizer Inc., Roche, and UCB. J. Silverfield has received research support from Pfizer Inc. E.B. Lee has served as a consultant for Pfizer Inc. J.R. Curtis has served as a consultant for, and has received research support from Pfizer Inc.; S.P. Wood, K. Soma, C.I. Nduaka, B. Benda, D. Gruben, H. Nakamura, Y. Komuro, S.H. Zwillich, L. Wang, and R.J. Riese are employees of Pfizer Inc. and hold stock/stock options in Pfizer Inc. Editorial support was provided by Karen Irving at Complete Medical Communications and was funded by Pfizer Inc. J. Wollenhaupt, MD, Head of Department of Rheumatology and Clinical Immunology, Schoen Klinik Hamburg; J. Silverfield, MD, Partner, Healthpoint Medical Group; E.B. Lee, MD, PhD, Professor of Medicine, Seoul National University; J.R. Curtis, MD, MS, MPH, Associate Professor of Medicine, The University of Alabama at Birmingham; S.P. Wood, RN, MA, Clinician; K. Soma, MD, MFPM, Director, Clinical Development; C.I. Nduaka, DVM, PhD, Medical Director; D. Gruben, PhD, Statistician; S.H. Zwillich, MD, Senior Director, Medicines Development Group Lead for Tofacitinib RA; L. Wang, MD, Clinician/Director; R.J. Riese, MD, PhD, Senior Director, Clinical Development, Pfizer Inc., Groton; B. Benda, MD, PhD, Senior Medical Director, Pfizer Inc., Collegeville; H. Nakamura, BS, Japan Clinical Lead; Y. Komuro, BS, Japan Clinical Lead, Pfizer Japan Inc. Address correspondence to Prof. Wollenhaupt, Head of Department of Rheumatology and Clinical Immunology, Schoen Klinik Hamburg, Teaching Hospital of the University of Hamburg, Dehnhaide 120, 11081 Hamburg, Germany. E-mail: Wollenhaupt@rheumatologikum.de. Full Release Article. For details see Reprints/Permissions at jrheum.org Accepted for publication November 19, 2013.
Lisy Wang
From the Schoen Klinik Hamburg, Hamburg, Germany; Healthpoint Medical Group, Tampa, Florida, USA; Seoul National University, Seoul, Republic of Korea; The University of Alabama at Birmingham, Birmingham, Alabama; Pfizer Inc., Groton, Connecticut; Pfizer Inc., Collegeville, Pennsylvania, USA; Pfizer Japan Inc., Tokyo, Japan. Funded by Pfizer Inc. J. Wollenhaupt has served as a consultant and member of the Speaker’s bureau for Abbott, Chugai, Pfizer Inc., Roche, and UCB. J. Silverfield has received research support from Pfizer Inc. E.B. Lee has served as a consultant for Pfizer Inc. J.R. Curtis has served as a consultant for, and has received research support from Pfizer Inc.; S.P. Wood, K. Soma, C.I. Nduaka, B. Benda, D. Gruben, H. Nakamura, Y. Komuro, S.H. Zwillich, L. Wang, and R.J. Riese are employees of Pfizer Inc. and hold stock/stock options in Pfizer Inc. Editorial support was provided by Karen Irving at Complete Medical Communications and was funded by Pfizer Inc. J. Wollenhaupt, MD, Head of Department of Rheumatology and Clinical Immunology, Schoen Klinik Hamburg; J. Silverfield, MD, Partner, Healthpoint Medical Group; E.B. Lee, MD, PhD, Professor of Medicine, Seoul National University; J.R. Curtis, MD, MS, MPH, Associate Professor of Medicine, The University of Alabama at Birmingham; S.P. Wood, RN, MA, Clinician; K. Soma, MD, MFPM, Director, Clinical Development; C.I. Nduaka, DVM, PhD, Medical Director; D. Gruben, PhD, Statistician; S.H. Zwillich, MD, Senior Director, Medicines Development Group Lead for Tofacitinib RA; L. Wang, MD, Clinician/Director; R.J. Riese, MD, PhD, Senior Director, Clinical Development, Pfizer Inc., Groton; B. Benda, MD, PhD, Senior Medical Director, Pfizer Inc., Collegeville; H. Nakamura, BS, Japan Clinical Lead; Y. Komuro, BS, Japan Clinical Lead, Pfizer Japan Inc. Address correspondence to Prof. Wollenhaupt, Head of Department of Rheumatology and Clinical Immunology, Schoen Klinik Hamburg, Teaching Hospital of the University of Hamburg, Dehnhaide 120, 11081 Hamburg, Germany. E-mail: Wollenhaupt@rheumatologikum.de. Full Release Article. For details see Reprints/Permissions at jrheum.org Accepted for publication November 19, 2013.
Richard J. Riese
From the Schoen Klinik Hamburg, Hamburg, Germany; Healthpoint Medical Group, Tampa, Florida, USA; Seoul National University, Seoul, Republic of Korea; The University of Alabama at Birmingham, Birmingham, Alabama; Pfizer Inc., Groton, Connecticut; Pfizer Inc., Collegeville, Pennsylvania, USA; Pfizer Japan Inc., Tokyo, Japan. Funded by Pfizer Inc. J. Wollenhaupt has served as a consultant and member of the Speaker’s bureau for Abbott, Chugai, Pfizer Inc., Roche, and UCB. J. Silverfield has received research support from Pfizer Inc. E.B. Lee has served as a consultant for Pfizer Inc. J.R. Curtis has served as a consultant for, and has received research support from Pfizer Inc.; S.P. Wood, K. Soma, C.I. Nduaka, B. Benda, D. Gruben, H. Nakamura, Y. Komuro, S.H. Zwillich, L. Wang, and R.J. Riese are employees of Pfizer Inc. and hold stock/stock options in Pfizer Inc. Editorial support was provided by Karen Irving at Complete Medical Communications and was funded by Pfizer Inc. J. Wollenhaupt, MD, Head of Department of Rheumatology and Clinical Immunology, Schoen Klinik Hamburg; J. Silverfield, MD, Partner, Healthpoint Medical Group; E.B. Lee, MD, PhD, Professor of Medicine, Seoul National University; J.R. Curtis, MD, MS, MPH, Associate Professor of Medicine, The University of Alabama at Birmingham; S.P. Wood, RN, MA, Clinician; K. Soma, MD, MFPM, Director, Clinical Development; C.I. Nduaka, DVM, PhD, Medical Director; D. Gruben, PhD, Statistician; S.H. Zwillich, MD, Senior Director, Medicines Development Group Lead for Tofacitinib RA; L. Wang, MD, Clinician/Director; R.J. Riese, MD, PhD, Senior Director, Clinical Development, Pfizer Inc., Groton; B. Benda, MD, PhD, Senior Medical Director, Pfizer Inc., Collegeville; H. Nakamura, BS, Japan Clinical Lead; Y. Komuro, BS, Japan Clinical Lead, Pfizer Japan Inc. Address correspondence to Prof. Wollenhaupt, Head of Department of Rheumatology and Clinical Immunology, Schoen Klinik Hamburg, Teaching Hospital of the University of Hamburg, Dehnhaide 120, 11081 Hamburg, Germany. E-mail: Wollenhaupt@rheumatologikum.de. Full Release Article. For details see Reprints/Permissions at jrheum.org Accepted for publication November 19, 2013.
Article Information
jrheum.130683
PubMed
Published By
Print ISSN
Online ISSN
History
- Published online April 1, 2014.
Article Versions
- You are currently viewing a Latest version of this article (April 1, 2014 - 04:00).
- View the most recent version of this article
Copyright & Usage
© 2013 The Journal of Rheumatology
Author Information
- Jürgen Wollenhaupt,
- Joel Silverfield,
- Eun Bong Lee,
- Jeffrey R. Curtis,
- Susan P. Wood,
- Koshika Soma,
- Chudy I. Nduaka,
- Birgitta Benda,
- David Gruben,
- Hiroyuki Nakamura,
- Yoshihiro Komuro,
- Samuel H. Zwillich,
- Lisy Wang and
- Richard J. Riese
- From the Schoen Klinik Hamburg, Hamburg, Germany; Healthpoint Medical Group, Tampa, Florida, USA; Seoul National University, Seoul, Republic of Korea; The University of Alabama at Birmingham, Birmingham, Alabama; Pfizer Inc., Groton, Connecticut; Pfizer Inc., Collegeville, Pennsylvania, USA; Pfizer Japan Inc., Tokyo, Japan.
Funded by Pfizer Inc. J. Wollenhaupt has served as a consultant and member of the Speaker’s bureau for Abbott, Chugai, Pfizer Inc., Roche, and UCB. J. Silverfield has received research support from Pfizer Inc. E.B. Lee has served as a consultant for Pfizer Inc. J.R. Curtis has served as a consultant for, and has received research support from Pfizer Inc.; S.P. Wood, K. Soma, C.I. Nduaka, B. Benda, D. Gruben, H. Nakamura, Y. Komuro, S.H. Zwillich, L. Wang, and R.J. Riese are employees of Pfizer Inc. and hold stock/stock options in Pfizer Inc. Editorial support was provided by Karen Irving at Complete Medical Communications and was funded by Pfizer Inc.
J. Wollenhaupt, MD, Head of Department of Rheumatology and Clinical Immunology, Schoen Klinik Hamburg; J. Silverfield, MD, Partner, Healthpoint Medical Group; E.B. Lee, MD, PhD, Professor of Medicine, Seoul National University; J.R. Curtis, MD, MS, MPH, Associate Professor of Medicine, The University of Alabama at Birmingham; S.P. Wood, RN, MA, Clinician; K. Soma, MD, MFPM, Director, Clinical Development; C.I. Nduaka, DVM, PhD, Medical Director; D. Gruben, PhD, Statistician; S.H. Zwillich, MD, Senior Director, Medicines Development Group Lead for Tofacitinib RA; L. Wang, MD, Clinician/Director; R.J. Riese, MD, PhD, Senior Director, Clinical Development, Pfizer Inc., Groton; B. Benda, MD, PhD, Senior Medical Director, Pfizer Inc., Collegeville; H. Nakamura, BS, Japan Clinical Lead; Y. Komuro, BS, Japan Clinical Lead, Pfizer Japan Inc.
Address correspondence to Prof. Wollenhaupt, Head of Department of Rheumatology and Clinical Immunology, Schoen Klinik Hamburg, Teaching Hospital of the University of Hamburg, Dehnhaide 120, 11081 Hamburg, Germany. E-mail: Wollenhaupt@rheumatologikum.de.
Full Release Article. For details see Reprints/Permissions at jrheum.org Accepted for publication November 19, 2013.
Article usage
Statistics from Altmetric.com
In this issue
The Journal of Rheumatology
Vol. 51, Issue 4
1 Apr 2024
Safety and Efficacy of Tofacitinib, an Oral Janus Kinase Inhibitor, for the Treatment of Rheumatoid Arthritis in Open-label, Longterm Extension Studies
Jürgen Wollenhaupt, Joel Silverfield, Eun Bong Lee, Jeffrey R. Curtis, Susan P. Wood, Koshika Soma, Chudy I. Nduaka, Birgitta Benda, David Gruben, Hiroyuki Nakamura, Yoshihiro Komuro, Samuel H. Zwillich, Lisy Wang, Richard J. Riese
The Journal of Rheumatology Apr 2014, jrheum.130683; DOI: 10.3899/jrheum.130683
Safety and Efficacy of Tofacitinib, an Oral Janus Kinase Inhibitor, for the Treatment of Rheumatoid Arthritis in Open-label, Longterm Extension Studies
Jürgen Wollenhaupt, Joel Silverfield, Eun Bong Lee, Jeffrey R. Curtis, Susan P. Wood, Koshika Soma, Chudy I. Nduaka, Birgitta Benda, David Gruben, Hiroyuki Nakamura, Yoshihiro Komuro, Samuel H. Zwillich, Lisy Wang, Richard J. Riese
The Journal of Rheumatology Apr 2014, jrheum.130683; DOI: 10.3899/jrheum.130683